Falsified Medical Product Alert N°5/2022
DIPRIVAN (propofol): falsified product alert
WHO issued this alert on falsified DIPRIVAN, an intravenous anaesthetic, identified in Venezuela in July 2022 and reported to WHO in August 2022. WHO said the safety, sterility and quality of the products are unknown. Indicators include printing and spelling errors and an inconsistent fill line among vials.1
- Issued
- 25 August 2022
- Issued by
- World Health Organization
- Name stated on packaging
- Packaging bears the DIPRIVAN brand, made by AstraZeneca for Aspen, with lot numbers WHO said were never issued for DIPRIVAN.
- Genuine manufacturer's statement
- WHO said Aspen and AstraZeneca confirmed the products are falsified because they deliberately or fraudulently misrepresent their identity and source.
- Countries where detected
- Venezuela (Bolivarian Republic of)
Batches named in the alert
Lot numbers are listed in the annex to the alert. WHO said the stated lot numbers are falsified.
Advice as stated
Do not use the listed products. Obtain medicines only from authorised or licensed suppliers and check their authenticity and condition. Report adverse events or suspected falsification to the national regulatory authority or pharmacovigilance centre.
Names printed on falsified products are not evidence that the named company made them. Where WHO or a regulator reports the genuine manufacturer's statement, it is shown.
Sources
- World Health Organization, Medical Product Alert N°5/2022: DIPRIVAN (25 August 2022)